30 closest matches · ranked by relevance
Food Protein-Induced Enterocolitis Syndrome · Allergies · Pediatric Disorder
Primary: Negative Predictive Value (NPV), Defined as the Percentage of Test-predicted Safe Foods That Are Actually Safe Foods. — 98.5; 73.16 percentage — p=<0.0001
Overweight and Obesity
Primary: Weight (kg) — 80; 76.6; 74.7; 75 kilograms
Eosinophilic Gastrointestinal Disorders (EGIDs) · Eosinophilic Esophagitis (EoE)
Primary: Percent of Participants in Histologic Remission (<15 Eos/Hpf) — 34.3; 40.3 percentage of participants — p=0.58
Food Allergy
Primary: 600mg Desensitization in at Least One Qualifying Food — 8; 11; 4 Participants
Food Allergy · Food Allergy Peanut
Primary: Highest Dose of Peanut That is Tolerated During Oral Food Challenge — 29; 4,044 mg — p=0.002
Peanut Hypersensitivity · Food Hypersensitivity · Hypersensitivity
Primary: Percentage of Subjects With a Successful Treatment Response — 12.0; 45.8; 48.0 percentage of participants — p=0.005
Food Allergy
Primary: The Number of Participants Able to Tolerate an Oral Food Challenge to 2,000 mg at Least of 2 Allergens at Week 36 (i.e. the End of the Randomized Withdrawal/Tolerance…
Food Allergy
Primary: Number of the Patients That Achieve Higher Tolerance of Allergen With Immunotherapy — 6; 4; 3 participants
Gastrointestinal Disorder, Functional
Primary: Most Common Triggers for Food-related GI Symptoms (Top 5) — 881; 494; 469; 460 Participants
Peanut Allergy · Multi-food Allergy
Primary: Number of Participants by Stage 1 Treatment Assignment, Omalizumab Versus Placebo, Who Successfully Consume a Single Dose of ≥600 mg of Peanut Protein Without…
Food Allergy
Primary: Desensitisation — 7; 5; 2 Participants
Food Hypersensitivity
Primary: The Level of Allergen Consumed Post-oral Immunotherapy — 6; 300 milligrams
Milk Allergy
Primary: Percentage of Subjects in the Xolair® (Omalizumab) Group vs. Placebo Group Developing Clinical Tolerance to Milk — 46.4; 34.5 Percent of participants — p=0.42
Milk Hypersensitivity
Primary: Number of Subjects Who Completed Desensitization Protocol — 6; 12 participants
Irritable Bowel Syndrome
Primary: Number of Participants With Worsening Irritable Bowel Syndrome (IBS) Symptoms Based on IBS-SSS — 8; 10; 11 Participants
Eosinophilic Esophagitis · Eosinophilic Gastrointestinal Disorders (EGIDs)
Primary: Change From Baseline in Pediatric EoE Symptom Score Version 2.0 (PEESS V2.0) at 12 Weeks — -14.3; -21.6 units on a scale — p=0.04
Food Allergy
Primary: Change in Allergen-specific Serum IgG4 and IgE — 578.5; 738.5 Total serum IgE (kU/L)
Eosinophilic Esophagitis
Primary: Percentage of Histologic Responders — 21 percentage of participants
Allergy to Shrimp · Immunotherapy
Primary: Change in Eliciting Dose of Shrimp During Oral Food Challenge — 3233; 25 mg
Hypersensitivity · Food Allergy · Hypersensitivity, Food
Primary: The Success Rates of Passing a Peanut Double-Blind Placebo Controlled Food Challenge (DBPCFC) — 19; 27; 3 Participants — p=0.16
Dentin Hypersensitivity
Primary: Hypersensitivity Tactile(Yeaple Probe) — 19.81; 13.94 units on a scale — p=0.05
Eosinophilic Esophagitis
Primary: Esophageal Eosinophilia (Number of Eosinophils in the Esophagus) — 5.3 eosinophils/high power field
Food Allergy · Anaphylaxis Food
Primary: Number of Doses of Ibrutinib for Maximal Suppression of Skin Prick Test Size to Foods — 2 doses — p=<0.0001
Food Allergy
Primary: Desensitization Measured by Proportion of Food Allergic (FA) Participants Who Pass a DBPCFC to 2,000 mg Protein for Each of 2 Allergens at Week 36 — 30; 4 Participants
Cow's Milk Allergy
Primary: Hypoallergenicity as Assessed by Reaction to Amino-acid Based Infant Formula — 0; 0; 0; 30 Participants
Peanut Allergy · Food Allergy
Primary: Tolerance of 2000 mg 6 Weeks After Last Dose of Omalizumab/Placebo — 23; 1 Participants
Infant Development · Gut Microbiome · Food Protein Induced Allergic Proctocolitis
Primary: Changes to Gut Microbiome Composition — 42.816; -12.413 Change in %B.infantis reads (Day 28-BL) — p=0.154
Eosinophilic Esophagitis
Primary: Sensitivity of Patch Testing — 1 Participants
Peanut Allergy
Primary: Consistency of High Threshold Reactivity — 6 Participants
Peanut Allergic Subjects
Primary: Determine the Percentage of Patients Tolerating the 12-month DBPCFC — 2; 10 Participants